Biogen Inc. (NASDAQ:BIIB) has long maintained a dominant position in the multiple sclerosis market. The drugmaker is now expanding into other autoimmune and neurological diseases like Alzheimer’s. And has also marked its foothold in hemophilia treatment market and biosimilars.
However, lately the company announced that it is considering spinning off its hemophilia business into a separate business entity to focus on its star franchises. Earlier this month, in a conference call with analysts, CEO George Scangos said: “We believe that the potential of Biogen can best be realized through a strategy that is dedicated to and focused on neuroscience,” while talking about spin off plans.
However, lately the company announced that it is considering spinning off its hemophilia business into a separate business entity to focus on its star franchises. Earlier this month, in a conference call with analysts, CEO George Scangos said: “We believe that the potential of Biogen can best be realized through a strategy that is dedicated to and focused on neuroscience,” while talking about spin off plans.
